KDIGO guideline for the care of kidney transplant recipients will be resource challenged

Kidney International

Volumn 77, Issue 4, 2010, Pages 271-272

  Delmonico, Francis L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; GENERIC DRUG; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANEMIA; BONE DISEASE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DEVELOPING COUNTRY; DISEASE ASSOCIATION; DRUG COST; ECONOMIC ASPECT; GENITAL SYSTEM; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GROWTH, DEVELOPMENT AND AGING; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY DONOR; KIDNEY GRAFT; MINERAL DEFICIENCY; NEOPLASM; NOTE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 75749118308     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.468     Document Type: Note

References (5)

1. Kasiske BL, Zeier MG, Chapman JR et al. K D I G O clinical practice guideline for the care of kidney transplant recipients: a summary. K idney Int 2010; 77: 299-311.
2. KDIGO clinical practice guideline for the care of kidney transplant recipients. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. Am J Transplant 2009; 9(Suppl 3): S1-S157.
3. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease. Kidney Disease: Improving Global Outcomes. Kidney Int Suppl 2008; (Suppl 109): S1-S99.
4. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. Kidney Int Suppl 2009; (Suppl 113): S1-S130.
5. Abbud-Filho M, Adams PL, Alber ú J et al. A report of the Lisbon Conference on the care of the kidney transplant recipient. Transplantation 2007;83 (Suppl 8):S1-S22. (Pubitemid 46653086)